INTEGRATIVE ONCOLOGY EVIDENCE REVIEW

Yoon Hang Kim, MD, MPH  |  Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Direct Integrative Care  |  Membership-Based Integrative Medicine Practice

Introduction: A Question of Risk — and Nuance

Complementary and alternative medicine (CAM) occupies a contested space in oncology. Patients increasingly seek it — surveys suggest roughly one-third of cancer patients use some form of CAM in any given year — and clinicians face recurring questions about its safety, efficacy, and implications for conventional treatment adherence. Two landmark studies from Yale University, separated by nearly a decade but connected by methodology and message, have produced some of the most rigorous population-level evidence to date on this question. Together, they offer a nuanced but genuinely important clinical signal: CAM use, particularly when it displaces conventional cancer treatment, is associated with significantly higher mortality.

This evidence review examines both studies in detail, addresses their methodological strengths and limitations, and draws clinically actionable conclusions for integrative oncology practice — including what this data means for the responsible integration of evidence-based complementary therapies alongside, not instead of, proven oncologic care.

Study 1: The 2018 Johnson et al. Analysis (JAMA Oncology)

Background and Design

Published in JAMA Oncology in 2018, this analysis by Dr. Skyler Johnson and colleagues at Yale drew on the National Cancer Database (NCDB), which captures approximately 70% of newly diagnosed cancers nationwide. From a base of nearly 1.9 million patients, the investigators identified 1,290 patients with breast, prostate, lung, or colorectal cancer for whom detailed treatment-choice data was available, comparing 258 CAM users to 1,032 matched controls receiving conventional cancer treatment (CCT) alone.

CAM use in this dataset was defined as treatment modalities outside conventional oncology — including vitamins and supplements, herbal medicine, mind-body practices, homeopathy, and traditional Chinese medicine — as recorded in the NCDB from 2004 to 2013.

Key Mortality Findings

CAM users experienced significantly worse overall survival:

• Hazard ratio for death (CAM vs. no CAM): 2.08 (95% CI, 1.50–2.90)
• 5-year overall survival: 82.2% (CAM) vs. 86.6% (no CAM)
• Breast cancer: 84.8% vs. 90.4% (5-year OS)
• Colorectal cancer: 81.8% vs. 84.4% (5-year OS)

The Critical Mechanistic Finding: Treatment Refusal as Mediator

The most clinically significant and conceptually important finding was what happened when the investigators adjusted for treatment refusal and delay. When refusal of conventional oncologic therapy — including chemotherapy, surgery, radiation, or hormone therapy — was added to the statistical model, the hazard ratio dropped to 1.39 (95% CI, 0.83–2.33), which was no longer statistically significant.

This mediation analysis reveals that CAM itself was not the proximate cause of increased mortality. Rather, patients who pursued CAM were significantly more likely to refuse or delay evidence-based oncologic therapies, and it was that treatment gap — not the CAM modalities themselves — that drove the survival difference. As Dr. Johnson noted: "The fact that complementary medicine use is associated with higher refusal of proven cancer treatments as well as increased risk of death should give providers and patients pause."

Key Insight: CAM use is a marker for treatment hesitancy, not an independent cause of cancer mortality.

The implication is not that CAM is inherently lethal — it is that patients pursuing CAM are at elevated risk of undertreating their cancer.

Study 2: The 2026 Ayoade et al. Analysis (JAMA Network Open)

An Expanded, More Granular Dataset

Published on March 2, 2026 in JAMA Network Open, this follow-up analysis by Dr. Oluwaseun F. Ayoade, Dr. Daniel Boffa, and colleagues at Yale dramatically expanded the evidence base. The study examined approximately 2.16 million women with breast cancer identified from the NCDB (2011–2021), making it one of the largest real-world oncology treatment-outcome analyses ever conducted on this question.

Treatment categories were defined as: traditional therapy alone (97.6%), CAM alone (<0.1%), combination CAM plus traditional therapy (<0.1%), or no treatment (2.3%).

Mortality Findings by Treatment Group

Compared to patients receiving traditional therapy alone:

• CAM alone: aHR 3.67 (95% CI, 3.03–4.44) — nearly identical to no treatment (aHR 3.53)
• No treatment: aHR 3.53 (95% CI, 3.48–3.58)
• CAM + traditional therapy: aHR 1.45 — 45% higher adjusted mortality risk

The raw 5-year survival figures underscore this starkly: 60.1% survival in CAM-only patients vs. 85.4% in traditional therapy patients. Women choosing CAM as their sole treatment fared no better than those who chose no treatment at all.

The Combination Therapy Paradox

A particularly counterintuitive finding was that even combining CAM with traditional therapies was associated with worse outcomes than traditional therapy alone. This group showed a 45% higher adjusted risk of death. Mechanistic analysis revealed why: combination therapy patients were significantly more likely to receive incomplete conventional treatment.

• Stage II CAM + traditional therapy patients received endocrine therapy at a rate of 40.7%, compared to 65.2% in traditional-therapy-only patients
• Radiation receipt: 59.5% vs. 36.6% (stage II, traditional vs. CAM combination)

Senior author Dr. Daniel Boffa acknowledged the team's surprise at this finding: "We were surprised that the combination group also did worse, because there is some evidence that CAM can reduce the side effects of traditional treatments." The data suggests that CAM adoption — even when combined with conventional therapy — correlates with less complete treatment adherence.

Comparative Summary of Both Yale Studies

An Integrative Oncology Perspective: What This Data Actually Tells Us

These findings are important, but they require careful contextual interpretation. The data does not indict the responsible integration of evidence-based complementary therapies. It indicts treatment substitution — the replacement of proven, stage-appropriate conventional oncologic therapy with unproven alternatives. That distinction is both clinically and ethically critical.

1. "Alternative" vs. "Complementary" — A Distinction That Costs Lives

The word "alternative" in CAM is doing significant harm in patient decision-making. In both Yale studies, the mortality signal is driven by patients who use CAM instead of conventional treatment, or who use it alongside conventional treatment in ways that lead to refusing key components (surgery, chemotherapy, radiation, endocrine therapy). Legitimate integrative oncology — as defined by the Society for Integrative Oncology and practiced at major cancer centers — does not involve this trade-off.

Integrative oncology, properly practiced, employs evidence-based complementary strategies — acupuncture for chemotherapy-induced nausea, mind-body approaches for anxiety and fatigue, targeted nutritional support, low-dose naltrexone as an immunomodulatory adjunct, modified citrus pectin, medicinal mushroom preparations — within the framework of conventional oncologic care, not as a substitute for it.

2. Why Patients Choose Alternative Treatment: The Communication Failure

These studies do not explain why patients pursue CAM in lieu of conventional treatment — but the clinical literature and patient narratives point to several well-documented drivers: fear of treatment toxicity, distrust of the medical system, spiritual or philosophical frameworks preferring "natural" therapies, financial barriers to conventional care, and — critically — a perceived failure of conventional providers to engage meaningfully with their questions about complementary approaches.

As Dr. Ayoade's team noted, the fact that younger women with higher educational attainment are among those more likely to choose CAM challenges simple assumptions about health literacy. These patients are often highly informed — but perhaps inadequately counseled. When integrative medicine providers fail to offer guidance, or when oncologists dismiss CAM questions without discussion, patients are left to make high-stakes decisions in an information vacuum.

3. The Shared Decision-Making Imperative

The Ayoade et al. team offered a constructive clinical takeaway: "Inviting patients to share their interest in CAM may present an opportunity to enhance shared decision-making, particularly as patients may be planning to forego traditional treatments." This is the correct clinical response to this evidence — not a reflexive dismissal of all complementary therapies, but a proactive conversation that brings CAM interest into the open, addresses it thoughtfully, and ensures it does not become a vehicle for treatment refusal.

Clinical Recommendation: Ask every oncology patient about CAM use at every visit.

The goal is not to prohibit — it is to ensure complementary approaches are being used to enhance, not replace, evidence-based treatment.

4. What the Data Does Not Tell Us

Several important limitations of both studies merit acknowledgment:

• The NCDB CAM category is heterogeneous and likely underrepresents integrative oncology as practiced in academic medical centers. Patients receiving acupuncture for nausea at a major cancer center and patients choosing homeopathy instead of surgery are both captured under the same label.
• These are observational analyses — they cannot establish causality. Confounding by unmeasured variables (health beliefs, socioeconomic factors, disease burden, distance from cancer center) likely influences results.
• The 2018 study's analytical sample of 1,290 patients — drawn from a base of 1.9 million — reflects the rarity of documented CAM use in the NCDB, not the actual prevalence of CAM use, which survey data places near 33% of cancer patients.
• No data in either study examines specific CAM modalities. The heterogeneity of what "CAM" encompasses is enormous, and it is methodologically inappropriate to use these population findings to condemn any individual therapy.

Clinical Implications for Integrative Oncology Practice

From a population health perspective, several evidence-informed recommendations follow from this body of research:

Screen for Treatment Hesitancy

CAM interest is a clinically meaningful signal. Patients who express interest in alternative cancer treatments should be assessed for treatment hesitancy, fears about toxicity, and concerns about the recommended conventional plan. Address these directly rather than dismissing CAM inquiries.

Establish Integrative Oncology Frameworks

The appropriate clinical response to a patient's desire for a more holistic approach is not to choose between conventional and complementary care — it is to provide both, in proper relationship to each other. Well-established integrative oncology protocols can meaningfully improve quality of life, treatment adherence, and selected outcomes when deployed as adjuncts to standard of care.

Address Systemic Barriers to Conventional Care

In some cases, CAM substitution reflects financial or logistical barriers to conventional oncologic treatment rather than ideological preference. Awareness of this possibility is important, particularly in underserved populations.

Use Data, Not Judgment, in Patient Conversations

When patients raise CAM alternatives, clinicians should be able to present population-level outcome data — including the hazard ratios from these Yale studies — in a compassionate, non-coercive way. Informed patients who understand the stakes are more likely to make treatment decisions aligned with their own survival interests.

Conclusion

The combined evidence from the 2018 Johnson et al. and 2026 Ayoade et al. analyses represents the strongest population-level data yet available on the mortality consequences of using CAM as a cancer treatment substitute. The core finding — that patients who use CAM instead of, or in ways that displace, conventional oncologic therapy face substantially higher mortality risk — is consistent across both studies and should inform clinical practice and patient communication.

But the evidence demands one further inference: the solution is not to dismiss patient interest in complementary approaches. It is to practice integrative oncology with rigor and integrity — harnessing evidence-based complementary therapies in their appropriate role, while ensuring conventional cancer treatment is never left incomplete. The data from Yale tells us what happens when these boundaries are crossed. The clinical imperative is to ensure they are not.

For more information about integrative oncology consultations through Direct Integrative Care, including telemedicine options across Texas, Florida, Georgia, Iowa, Illinois, and Missouri, please visit our website.

References

1. Johnson SB, Park HS, Gross CP, Yu JB. Use of alternative medicine for cancer and its impact on survival. JAMA Oncol. 2018;4(10):1375-1381. doi:10.1001/jamaoncol.2018.2487

2. Ayoade OF, Caturegli G, Canavan ME, Resio BJ, Berger ER, Boffa DJ. Use of complementary and alternative medicine in the management of breast cancer. JAMA Netw Open. 2026;9(3):e260337. doi:10.1001/jamanetworkopen.2026.0337

3. Oberfeld B, et al. Complementary medicine use among US adult cancer patients. JAMA Oncol. 2019;doi:10.1001/jamaoncol.2019.0349

About Dr. Kim

Dr. Yoon Hang “John” Kim is board-certified with over 20 years of experience in Preventive Medicine and Integrative & Functional Medicine. He completed his integrative medicine fellowship under Dr. Andrew Weil at the University of Arizona (Osher Fellow), holds board certifications in both Preventive Medicine and Integrative/Holistic Medicine, earned his UCLA medical acupuncture certification, and holds IFM Scholar status. Dr. Kim specializes in LDN therapy, autoimmune disease, chronic pain, integrative oncology, fibromyalgia, CFS/ME, MCAS, and mold toxicity. He is the author of 3 books and over 20 peer-reviewed articles, and leads the LDN Support Group with more than 9,000 members.

Professional site: www.yoonhangkim.com  |  Clinical practice: www.directintegrativecare.com